Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/30/17 → 3/30/20 |
Funding
- Methodist Hospital Research Institute (Prot #NU HM16B03 // Prot #NU HM16B03)
- Novartis Pharmaceuticals Corporation (Prot #NU HM16B03 // Prot #NU HM16B03)
Prot #NU HM16B03: Neoadjuvant Phase II Study of Everolimus Plus Cisplatin in Triple Negative Breast Cancer Patients with Residual Disease After Standard Chemotherapy
- Cristofanilli, Massimo (PD/PI)
Project: Research project